Status: Recruiting
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Participants needed: 18
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Varun Monga, MBBSUpdated: Sep 1, 2026Locations: 1
Eligibility criteria
Participants with biopsy proven cutaneous angiosarcoma that is locally advanced... [+26]
Prior treatment with an oncolytic therapy. [+22]